Healthcare / Medical DevicesLSE
$18.40
+0.40 (+2.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-1.6M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$11M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.1%
↓Gross Margin
81.1%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2024 · 2 años de histórico normalizado
Revenue CAGR
+16.1%
FCF CAGR
—
FCF margin
-63.1%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.2M · net income $-1.4M · FCF $-1.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $2.2M | $2.2M | $2.2M | $1.6M |
| Net Income | $-1.4M | $-1.4M | $-2.0M | $-2.1M |
| EBITDA | $-1.6M | $-1.6M | $-2.0M | $-2.0M |
| EPS | -0.04 | -0.04 | -0.09 | -0.09 |
| Gross Margin | 81.1% | 81.1% | 82.2% | 83.6% |
| Operating Margin | -89.1% | -89.1% | -106.1% | -144.6% |
| Net Margin | -65.7% | -65.7% | -91.9% | -127.2% |
| Balance Sheet | ||||
| Debt/Equity | 0.05 | 0.05 | 0.10 | 0.05 |
| Current Ratio | 4.64 | 4.64 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-1.4M | $-1.4M | $-1.6M | $-3.3M |
| Returns | ||||
| ROE | -20.1% | -20.1% | -42.8% | -31.4% |
| Valuation | ||||
| P/B | 159.00 | 159.00 | 239.23 | 166.79 |
| Growth & Yield | ||||
| Revenue Growth | 0.6% | 0.6% | 34.1% | — |
| EPS Growth | 52.5% | 52.5% | 3.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.09 → -0.04
Residual
+56.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.